Berlin biotech platform developing psychedelic and other therapeutics for mental health disorders.
| Date | Round | Amount |
|---|---|---|
| Nov 2020 | Series C Berlin mental-health biotech ATAI Life Sciences raised a $125M Series C round co-led by Apeiron Investment Group, Peter Thiel and Catalio Capital Management. | $125M |